Global Primary Hyperoxaluria Treatment Market Size to Grow at a CAGR of 3.7% in the Forecast Period of 2023-2031

The ‘Global Primary Hyperoxaluria Treatment Market Size, Share, Price, Trends, Growth, Report and Forecast 2023-2031’ by Expert Market Research gives an extensive outlook of the global primary hyperoxaluria treatment market, assessing the market on the basis of its segments like type, diagnosis, treatment method, treatment channel and major regions. The report also provides a detailed insight of the market on the basis of patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnership and collaborations analysis.

The report studies the latest updates in the market, along with their impact across the market. It also analyzes the market demand, together with its price and demand indicators. The report also tracks the market on the basis of SWOT and Porter’s Five Forces Models.

Primary Hyperoxaluria Treatment Market Size, Share, Price, Trends, Growth, Key Players, Report and Forecast

The key highlights of the report include:

Market Overview (2016-2031)

• Forecast CAGR (2023-2031): 3.7%
• Forecast Market Size (2031): 25.2 Billion

Growing awareness pertaining to rare and genetic disorders is expected to drive the growth of the global primary hyperoxaluria treatment market. An increasing number of drugs in clinical trials by leading pharmaceutical companies for primary hyperoxaluria is expected to offer lucrative growth opportunities to the market. However, the availability of a small patient size for clinical trials is expected to pose a challenge for the primary hyperoxaluria treatment market.

Get a Free Sample Report with Table of Contents - https://www.expertmarketresearch.com/reports/primary-hyperoxaluria-treatment-market/requestsample

Advancements in genetic testing and the increasing adoption of next-generation sequencing (NGS) have led to improved diagnosis of primary hyperoxaluria. These advancements in the field of diagnosis are expected to have a positive impact on the global primary hyperoxaluria treatment market growth.

Over the forecast period, the anticipated increase in the development of various drugs to combat primary hyperoxaluria is expected to drive market growth. These developments, coupled with the growing demand for novel target therapies and the strengthening healthcare infrastructure, are likely to contribute to market growth.

Primary Hyperoxaluria Treatment Industry Definition and Major Segments

Primary hyperoxaluria is a rare genetic disorder that results in the overproduction of oxalate, leading to the formation of kidney stones and kidney damage. Symptoms of the disease include recurrent kidney stones, blood in the urine, and urinary tract infections, among others. Treatments include medication, dietary changes, and kidney transplantation.

Read Full Report with Table of Contents – https://www.expertmarketresearch.com/reports/primary-hyperoxaluria-treatment-market

Based on type, the market is segmented into:

• Primary Hyperoxaluria Type I
• Primary Hyperoxaluria Type II
• Primary Hyperoxaluria Type III

Based on the diagnosis, the market is classified into:

• Urine Tests
• Blood Tests
• Stone Analysis
• Kidney X-ray, Ultrasound or Computerized Tomography (CT) Scan
• DNA Testing
• Kidney Biopsy
• Echocardiogram
• Eye Exam
• Bone Marrow Biopsy
• Liver Biopsy

Based on treatment methods, the market is bifurcated into:

• Medications
  • Potassium Citrate
  • Thiazide Diuretics
  • Vitamin Supplements
  • Lumasiran
• High Fluid Intake
• Dietary Changes
• Kidney Stone Management
• Dialysis and Transplantation

Based on treatment channel, the market is bifurcated into:

• Public
• Private

Based on region, the market is segregated into:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Primary Hyperoxaluria Treatment Market Trends

The key trends in the global primary hyperoxaluria treatment market include the growing development and research by the healthcare sector, aimed towards the development of different drug combinations and targeted therapies to combat the rare genetic disorder.

Significant advancements in genetic testing have led to an improved understanding of primary hyperoxaluria, and these developments have significantly impacted the clinical management of patients. Novel approaches to minimize the side effects of various treatments have become the focus of many research studies. This development is expected to increase the number of patients suffering from primary hyperoxaluria receiving treatment, which in turn, is expected to contribute to global primary hyperoxaluria treatment market growth.

Increased clinical trials with targeted therapy and novel medications are projected to increase market growth. Development in radiological imaging has resulted in improved sensitivity in the detection of primary hyperoxaluria, and this development is also expected to impact the growth of the market.

Key Market Players

The major players in the global primary hyperoxaluria treatment market report are:

• Dicerna Pharmaceuticals, Inc.
• Alnylam Pharmaceuticals, Inc.
• OxThera
• Intellia Therapeutics, Inc.
• Sanofi
• Others

The report covers the market shares, capacities, plant turnarounds, expansions, investments, and mergers and acquisitions, among other latest developments of these market players.